# TOURMALINE-MM3 (NCT02181413)

> A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02181413
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: Multiple Myeloma; Autologous Stem Cell Transplant
- Interventions: Ixazomib Citrate; Placebo
- Enrollment: 656
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on TOURMALINE-MM3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tourmaline-mm3-nct02181413

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02181413", "email": "<work email>"}; the inbox owner confirms by the emailed link.